¼¼°èÀÇ ÇコÄɾî¿ë »ý¼ºÇü ÀΰøÁö´É ½ÃÀå
Generative Artificial Intelligence in Healthcare
»óǰÄÚµå : 1644034
¸®¼­Ä¡»ç : Global Industry Analysts, Inc.
¹ßÇàÀÏ : 2025³â 01¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 191 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,850 £Ü 8,136,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 17,550 £Ü 24,408,000
PDF (Global License to Company and its Fully-owned Subsidiaries) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

¼¼°èÀÇ ÇコÄɾî¿ë »ý¼ºÇü ÀΰøÁö´É ½ÃÀåÀº 2030³â±îÁö 170¾ï ´Þ·¯¿¡ µµ´Þ

2024³â¿¡ 27¾ï ´Þ·¯·Î ÃßÁ¤µÇ´Â ¼¼°èÀÇ ÇコÄɾî¿ë »ý¼ºÇü ÀΰøÁö´É ½ÃÀåÀº ºÐ¼® ±â°£ÀÎ 2024-2030³â¿¡ 36.0%ÀÇ CAGR·Î ¼ºÀåÇϸç, 2030³â¿¡´Â 170¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ÀÌ ¸®Æ÷Æ®¿¡¼­ ºÐ¼®ÇÑ ºÎ¹®ÀÇ ÇϳªÀÎ ÇコÄÉ¾î »ý¼ºÇü AI ¼Ö·ç¼ÇÀº CAGR 34.6%¸¦ ±â·ÏÇϸç, ºÐ¼® ±â°£ Á¾·á±îÁö 97¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ÇコÄÉ¾î »ý¼ºÇü AI ¼­ºñ½º ºÎ¹®ÀÇ ¼ºÀå·üÀº ºÐ¼® ±â°£¿¡ CAGR 38.1%·Î ÃßÁ¤µË´Ï´Ù.

¹Ì±¹ ½ÃÀåÀº 7¾ï 440¸¸ ´Þ·¯·Î ÃßÁ¤, Áß±¹Àº CAGR 34.3%·Î ¼ºÀå ¿¹Ãø

¹Ì±¹ÀÇ ÇコÄɾî¿ë »ý¼ºÇü ÀΰøÁö´É ½ÃÀåÀº 2024³â¿¡ 7¾ï 440¸¸ ´Þ·¯·Î ÃßÁ¤µË´Ï´Ù. ¼¼°è 2À§ÀÇ °æÁ¦´ë±¹ÀÎ Áß±¹Àº 2030³â±îÁö 25¾ï ´Þ·¯ÀÇ ½ÃÀå ±Ô¸ð¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, ºÐ¼® ±â°£ÀÎ 2024-2030³âÀÇ CAGRÀº 34.3%ÀÔ´Ï´Ù. ±âŸ ÁÖ¸ñÇØ¾ß ÇÒ Áö¿ªº° ½ÃÀåÀ¸·Î´Â ÀϺ»°ú ij³ª´Ù°¡ ÀÖÀ¸¸ç, ºÐ¼® ±â°£ Áß CAGRÀº °¢°¢ 32.7%¿Í 31.4%·Î ¿¹ÃøµË´Ï´Ù. À¯·´¿¡¼­´Â µ¶ÀÏÀÌ CAGR 25.3%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¼¼°èÀÇ ÇコÄɾî¿ë »ý¼ºÇü ÀΰøÁö´É ½ÃÀå - ÁÖ¿ä µ¿Çâ°ú ÃËÁø¿äÀÎ Á¤¸®

ÇコÄɾ¼­ »ý¼ºÇü AIÀÇ º¯ÇõÀû ´É·ÂÀº ¹«¾ùÀΰ¡?

»ý¼ºÇü ÀΰøÁö´ÉÀº º¹ÀâÇÑ µ¥ÀÌÅͼ¼Æ®¸¦ ºÐ¼®ÇÏ°í ¿¹Ãø ¸ðµ¨À» »ý¼ºÇÏ´Â ´É·ÂÀ» Ȱ¿ëÇÏ¿© ÀÇ·á ¼­ºñ½º¸¦ À籸¼ºÇϰí Áø´Ü, Ä¡·á ¹× ȯÀÚ Ä¡·áÀÇ È¹±âÀûÀÎ ¹ßÀüÀ» °¡´ÉÇÏ°Ô Çϰí ÀÖ½À´Ï´Ù. ¹æ´ëÇÑ ¾çÀÇ È¯ÀÚ µ¥ÀÌÅÍ, ÀÇ·á ±â·Ï, À̹ÌÁö ½ºÄµÀ» Ȱ¿ëÇÏ¿© AI ¾Ë°í¸®ÁòÀº Á¤È®ÇÏ°í ½Ã±âÀûÀýÇÑ ÀλçÀÌÆ®À» Á¦°øÇÔÀ¸·Î½á ÀÓ»ó °á°ú¸¦ Å©°Ô Çâ»ó½Ãų ¼ö ÀÖ½À´Ï´Ù. ±âÁ¸ ÆÐÅÏ¿¡¼­ »õ·Î¿î µ¥ÀÌÅ͸¦ »ý¼ºÇÏ´Â »ý¼ºÇü AIÀÇ ´É·ÂÀº ¿µ»ó Áø´Ü¿¡ ƯÈ÷ À¯¿ëÇϸç, ¾Ï, ½ÉÀ庴, ½Å°æÁúȯ°ú °°Àº Áúº´À» ŸÀÇ ÃßÁ¾À» ºÒÇãÇÏ´Â Á¤È®µµ·Î ½Äº°ÇÒ ¼ö ÀÖ½À´Ï´Ù. Áø´Ü¿¡ ±×Ä¡Áö ¾Ê°í, ÀÌ ±â¼úÀº º¹ÀâÇÑ »ý¹°ÇÐÀû ½Ã½ºÅÛÀ» ¸ðµ¨¸µÇϰí Áúº´ ÁøÇà°ú Ä¡·á È¿°ú¸¦ ½Ç¸®ÄÜ ³»¿¡¼­ ½Ã¹Ä·¹À̼ÇÇÒ ¼ö ÀÖ°Ô ÇÔÀ¸·Î½á ºñ¿ë°ú ½Ã°£ÀÌ ¸¹ÀÌ µå´Â ¹°¸®Àû ½ÇÇè¿¡ ´ëÇÑ ÀÇÁ¸µµ¸¦ ³·Ãâ ¼ö ÀÖ°Ô ÇÕ´Ï´Ù. ¸ÂÃãÇü ÀÇ·á´Â »ý¼ºÇü AIÀÇ ÁÖ¿ä ÀÀ¿ë »ç·Ê·Î µîÀåÇß½À´Ï´Ù. AI´Â ȯÀÚ °³°³ÀÎÀÇ À¯ÀüÀÚ ¹× »ýȰ½À°ü ÇÁ·ÎÆÄÀÏ¿¡ ¸ÂÃß¾î Ä¡·á¸¦ Á¶Á¤ÇÔÀ¸·Î½á ºÎÀÛ¿ëÀ» ÃÖ¼ÒÈ­Çϸ鼭 ÃÖÀûÀÇ Ä¡·á¸¦ ½ÇÇöÇÒ ¼ö ÀÖ½À´Ï´Ù. ¶ÇÇÑ ÀÌ ±â¼úÀº Èñ±ÍÇÏ°í º¹ÀâÇÑ Áúº´À» ½Ã¹Ä·¹À̼ÇÇÏ¿© ÀÇ·á ±³À° ¹× ÈÆ·ÃÀ» Áö¿øÇϰí, ÀÓ»óÀǰ¡ ÅëÁ¦µÈ ȯ°æ¿¡¼­ ±â¼úÀ» ¿¬¸¶ÇÒ ¼ö ÀÖµµ·Ï µ½½À´Ï´Ù. »ý¼ºÇü AIÀÇ ÀÌ·¯ÇÑ º¯ÇõÀû ´É·ÂÀº ÀÇ·á ¼­ºñ½º Á¦°øÀÇ ¹Ì·¡¸¦ À§ÇÑ Ãʼ®À¸·Î ÀÚ¸®¸Å±èÇϰí ÀÖ½À´Ï´Ù.

Á¦¾à¾÷°è°¡ »ý¼ºÇü AI µµÀÔÀÇ ÃÖÀü¼±¿¡ ÀÖ´Â ÀÌÀ¯´Â ¹«¾ùÀΰ¡?

Á¦¾à¾÷°è´Â ÀΰøÁö´É(AI)ÀÌ ¾à¹° ¹ß°ß°ú °³¹ßÀ» °¡¼ÓÈ­Çϸ鼭 ÆÐ·¯´ÙÀÓÀÇ ÀüȯÀ» °æÇèÇϰí ÀÖ½À´Ï´Ù. AI ±â¹Ý Ç÷§ÆûÀº À¯¸ÁÇÑ ºÐÀÚ È­ÇÕ¹°À» ½Äº°Çϰí, »óÈ£ ÀÛ¿ëÀ» ½Ã¹Ä·¹À̼ÇÇϰí, ¾à¸®ÇÐÀû Ư¼ºÀ» ¿¹ÃøÇÔÀ¸·Î½á ÀüÀÓ»ó ´Ü°è¸¦ °£¼ÒÈ­ÇÏ¿© ½Å¾à Ãâ½Ã¿¡ ¼Ò¿äµÇ´Â ¸·´ëÇÑ ½Ã°£°ú ºñ¿ëÀ» Å©°Ô Àý°¨ÇÒ ¼ö ÀÖ½À´Ï´Ù. »ý¼ºÇü AI´Â °¡»ó ÀǾàǰ Å×½ºÆ®¿Í °è»ê ¿¹ÃøÀ» ¿ëÀÌÇÏ°Ô ÇÔÀ¸·Î½á Èı⠴ܰèÀÇ ½ÇÆÐ °¡´É¼ºÀ» ÃÖ¼ÒÈ­Çϰí, ´õ ³ôÀº ¼º°ø·ü°ú ºü¸¥ ½ÂÀÎ ÇÁ·Î¼¼½º¸¦ º¸ÀåÇÕ´Ï´Ù. ÀǾàǰ Àç»ç¿ë¿¡ À־µµ AIÀÇ ¿ªÇÒÀº °ÔÀÓ Ã¼ÀÎÀúÀÓÀÌ ÀÔÁõµÇ°í ÀÖ½À´Ï´Ù. ±âÁ¸ µ¥ÀÌÅͼ¼Æ®¸¦ ºÐ¼®ÇÏ°í ±âÁ¸ ¾à¹°ÀÇ »õ·Î¿î ¿ëµµ¸¦ Ž»öÇÔÀ¸·Î½á Á¦¾à»ç´Â ¹ÌÃæÁ· ÀÇ·á ¼ö¿ä¿¡ È¿À²ÀûÀ¸·Î ´ëÀÀÇÒ ¼ö ÀÖ½À´Ï´Ù. ¶ÇÇÑ »ý¼ºÇü AI´Â ÃÖÀûÀÇ È¯ÀÚ ÄÚȣƮ¸¦ ¼±ÅÃÇϰí, ½ÃÇè ÇÁ·ÎÅäÄÝÀ» ÁؼöÇϰí, ½Ç½Ã°£ µ¥ÀÌÅ͸¦ ºÐ¼®ÇÏ¿© ÀÌ»ó ¡Èĸ¦ ½Äº°ÇÔÀ¸·Î½á ÀÓ»ó½ÃÇè °ü¸®¸¦ °­È­ÇÕ´Ï´Ù. ÀÌ·¯ÇÑ Çõ½ÅÀº ÀǾàǰ °³¹ßÀÇ ¼Óµµ¿Í Á¤È®¼ºÀ» Çâ»ó½Ãų »Ó¸¸ ¾Æ´Ï¶ó ºñ¿ë È¿À²¼º¿¡µµ ±â¿©ÇÏ¿© Áß¿äÇÑ Ä¡·áÁ¦ÀÇ ÆÄÀÌÇÁ¶óÀÎÀ» ´õ¿í °ß°íÇÏ°Ô À°¼ºÇÒ ¼ö ÀÖ½À´Ï´Ù.

ÀÇ·á ¼­ºñ½º ÇÁ·Î¹ÙÀÌ´õ´Â ¾î¶»°Ô »ý¼ºÇü AI¸¦ ¾÷¹«¿¡ ÅëÇÕÇϰí Àִ°¡?

º´¿ø°ú ÀÇ·á ¼­ºñ½º ÇÁ·Î¹ÙÀÌ´õµéÀº ¾÷¹« È¿À²¼º, ȯÀÚ °ü¸® ¹× ÀÚ¿ø Ȱ¿ëÀ» °³¼±Çϱâ À§ÇØ AI¸¦ µµÀÔÇϰí ÀÖÀ¸¸ç, AI ±â¹Ý ½Ã½ºÅÛÀº ¿¹¾à ¿¹¾à ¹× û±¸¿¡¼­ µ¥ÀÌÅÍ °ü¸® ¹× ÄÄÇöóÀ̾𽺠¸ð´ÏÅ͸µ¿¡ À̸£±â±îÁö °ü¸® ¿öÅ©Ç÷ο츦 Çõ½ÅÀûÀ¸·Î °³¼±ÇÏ¿© ÀÇ·áÁøÀÌ È¯ÀÚ¿ÍÀÇ Á÷Á¢ÀûÀÎ »óÈ£ÀÛ¿ë¿¡ ÁýÁßÇÒ ¼ö ÀÖµµ·Ï µ½°í ÀÖ½À´Ï´Ù. AI¸¦ ÀüÀڰǰ­±â·Ï(EHR)°ú ÅëÇÕÇϸé ÀÓ»óÀÇ´Â Á¤È®ÇÑ ÃֽŠÁ¤º¸¿¡ Á¢±ÙÇÒ ¼ö ÀÖÀ¸¸ç, º¸´Ù ½Å¼ÓÇϰí Á¤È®ÇÑ ÀÇ»ç°áÁ¤À» ³»¸± ¼ö ÀÖ°Ô µË´Ï´Ù. ¿ø°ÝÀÇ·á´Â AI ±â¹Ý °¡»ó ºñ¼­ ¹× Áø´Ü Åø¿¡ ÈûÀÔ¾î ºü¸£°Ô ¼ºÀåÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Ç÷§ÆûÀº ƯÈ÷ ÀÇ·á ¼­ºñ½º°¡ ºÎÁ·ÇÑ Áö¿ª°ú ³óÃÌ Áö¿ª¿¡¼­ ½Ç½Ã°£ ÀλçÀÌÆ®¿Í ¸ð´ÏÅ͸µ ±â´ÉÀ» Á¦°øÇÔÀ¸·Î½á ¿ø°Ý Áø·áÀÇ ÁúÀ» Çâ»ó½Ã۰í ÀÖ½À´Ï´Ù. ¶ÇÇÑ AI¸¦ Ȱ¿ëÇÑ ¿¹Ãø ºÐ¼®Àº ȯÀÚÀÇ ÀÔ¿ø Ãß¼¼¸¦ ¿¹ÃøÇϰí Á÷¿ø ¹èÄ¡¸¦ ÃÖÀûÈ­ÇÏ¿© º´¿øÀÇ ÀÚ¿ø °èȹÀ» Áö¿øÇÕ´Ï´Ù. »ý¼ºÇü ÀΰøÁö´É(AI)°¡ À¯µµÇÏ´Â ·Îº¿ º¸Á¶ ¼ö¼úÀº Á¤È®¼ºÀÇ »õ·Î¿î ±âÁØÀ» ¼³Á¤Çϰí ȸº¹ ½Ã°£À» ´ÜÃàÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ¹ßÀüÀº AI°¡ ÀÇ·á »ýŰ迡 ÅëÇյǰí ÀÖÀ½À» ¹Ý¿µÇϸç, ÀÇ·á ÇÁ·Î¹ÙÀÌ´õ¿Í ȯÀÚÀÇ °á°ú¸¦ È®½ÇÈ÷ °³¼±ÇÒ ¼ö ÀÖµµ·Ï ÇÕ´Ï´Ù.

ÇコÄÉ¾î ºÐ¾ßÀÇ »ý¼ºÇü AI ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇÏ´Â ¿äÀÎÀº ¹«¾ùÀΰ¡?

ÇコÄÉ¾î ºÐ¾ßÀÇ »ý¼ºÇü ÀΰøÁö´É ½ÃÀåÀÇ ¼ºÀåÀº ÇコÄÉ¾î µ¥ÀÌÅÍ ¾ç Áõ°¡, ÄÄÇ»ÆÃ ¼º´ÉÀÇ ¹ßÀü, °³ÀÎÈ­µÈ ÀÇ·á ¼­ºñ½º¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡ µî ¸î °¡Áö Áß¿äÇÑ ¿äÀο¡ ÀÇÇØ ÁÖµµµÇ°í ÀÖ½À´Ï´Ù. Á¦¾àȸ»çµéÀÇ AI µµÀÔÀº º¸´Ù ºü¸¥ ½Å¾à°³¹ß°ú ºñ¿ë Àý°¨À» °¡´ÉÄÉ ÇÏ´Â Ã˸ÅÁ¦ ¿ªÇÒÀ» Çϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ ¿ø°ÝÀÇ·á ¼­ºñ½º ¹× ¿ø°ÝÀÇ·á ¼Ö·ç¼ÇÀÇ È®´ë´Â ƯÈ÷ ÀÇ·á Á¢±Ù¼ºÀÌ Á¦ÇÑµÈ Áö¿ª¿¡¼­ ¿øÈ°Çϰí È¿À²ÀûÀΠȯÀÚ °ü¸®¸¦ ÃËÁøÇÏ´Â AI ±â¹Ý Ç÷§Æû¿¡ ´ëÇÑ ¼ö¿ä¸¦ ÃËÁøÇϰí ÀÖ½À´Ï´Ù. Á¤¹ÐÀÇ·á¿Í ¸ÂÃãÇü Ä¡·á¿¡ ´ëÇÑ ¼ÒºñÀÚÀÇ ±â´ë´Â ÀÇ·á ¼­ºñ½º ÇÁ·Î¹ÙÀÌ´õµéÀÌ È¯ÀÚ ¸¸Á·µµ¿Í ÀÓ»ó °á°ú¸¦ Çâ»ó½Ãų ¼ö ÀÖ´Â AI ÅøÀ» µµÀÔÇϵµ·Ï À¯µµÇϰí ÀÖ½À´Ï´Ù. º¸Çè»çµéµµ ºÎÁ¤ÇàÀ§ °¨Áö, À§Çè Æò°¡, °³ÀÎÈ­µÈ º¸Çè °è¾à ÀÛ¼º¿¡ AI¸¦ Ȱ¿ëÇϰí ÀÖÀ¸¸ç, ÇコÄÉ¾î ºÐ¾ß Àü¹Ý¿¡ °ÉÃÄ AIÀÇ Àû¿ë ¹üÀ§°¡ È®´ëµÇ°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ Á¤ºÎ¿Í ¹Î°£ ±â°üÀº AI ¿¬±¸¿Í Çõ½Å¿¡ ¸¹Àº ÅõÀÚ¸¦ Çϰí ÀÖÀ¸¸ç, ±ÔÁ¦±â°üÀº AIÀÇ À±¸®Àû ¹èÆ÷¿Í »óÈ£¿î¿ë¼ºÀ» º¸ÀåÇϱâ À§ÇØ ³ë·ÂÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ¿ä¼ÒµéÀÇ ÃÑÇÕÀº ÇコÄÉ¾î ºÐ¾ß¿¡¼­ »ý¼ºÇü AIÀÇ º¯ÇõÀû ¿µÇâ·Â°ú ¼¼°è ÀÇ·á ½Ã½ºÅÛÀÇ ¹Ì·¡¸¦ Çü¼ºÇÏ´Â ¿ªÇÒÀ» °­Á¶Çϰí ÀÖ½À´Ï´Ù.

ºÎ¹®

ÄÄÆ÷³ÍÆ®(¼Ö·ç¼Ç ÄÄÆ÷³ÍÆ®, ¼­ºñ½º ÄÄÆ÷³ÍÆ®), ±â´É(ÀÇ·á ¿µ»ó ºÐ¼® ±â´É, °¡»ó °£È£ º¸Á¶ ±â´É, ·Îº¿ º¸Á¶ AI ¼ö¼ú ±â´É, »ç¹« ÇÁ·Î¼¼½º ÃÖÀûÈ­ ±â´É), ¿ëµµ(ÀÓ»ó ¿ëµµ, ½Ã½ºÅÛ ¿ëµµ), ÃÖÁ¾ ¿ëµµ(ÀÓ»ó ¿¬±¸ ÃÖÁ¾ ¿ëµµ, ÀÇ·á ¼¾ÅÍ ÃÖÁ¾ ¿ëµµ, Áø´Ü¼¾ÅÍ ÃÖÁ¾ ¿ëµµ, ±âŸ ÃÖÁ¾ ¿ëµµ)

Á¶»ç ´ë»ó ±â¾÷ÀÇ ¿¹(ÃÑ 27»ç¿¡ ÁÖ¸ñ)

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý

Á¦2Àå °³¿ä

Á¦3Àå ½ÃÀå ºÐ¼®

Á¦4Àå °æÀï

KSA
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Global Generative Artificial Intelligence in Healthcare Market to Reach US$17.0 Billion by 2030

The global market for Generative Artificial Intelligence in Healthcare estimated at US$2.7 Billion in the year 2024, is expected to reach US$17.0 Billion by 2030, growing at a CAGR of 36.0% over the analysis period 2024-2030. Healthcare Generative AI Solutions, one of the segments analyzed in the report, is expected to record a 34.6% CAGR and reach US$9.7 Billion by the end of the analysis period. Growth in the Healthcare Generative AI Services segment is estimated at 38.1% CAGR over the analysis period.

The U.S. Market is Estimated at US$704.4 Million While China is Forecast to Grow at 34.3% CAGR

The Generative Artificial Intelligence in Healthcare market in the U.S. is estimated at US$704.4 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$2.5 Billion by the year 2030 trailing a CAGR of 34.3% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 32.7% and 31.4% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 25.3% CAGR.

Global Generative Artificial Intelligence in Healthcare Market – Key Trends & Drivers Summarized

What Are the Transformative Capabilities of Generative AI in Healthcare?

Generative Artificial Intelligence is reshaping healthcare by leveraging its ability to analyze complex datasets and generate predictive models, enabling breakthroughs in diagnostics, treatment, and patient care. By harnessing vast volumes of patient data, medical records, and imaging scans, AI algorithms can deliver precise and timely insights that significantly enhance clinical outcomes. Generative AI's ability to create new data from existing patterns is particularly valuable in imaging diagnostics, where it identifies diseases such as cancer, heart conditions, and neurological disorders with unparalleled accuracy. Beyond diagnostics, the technology aids in modeling complex biological systems, allowing for the simulation of disease progression and treatment efficacy in silico, reducing the reliance on costly and time-intensive physical experiments. Personalized medicine has emerged as a flagship application of generative AI. By tailoring treatments to individual patients' genetic and lifestyle profiles, AI ensures optimized care with minimal adverse effects. Furthermore, the technology supports medical education and training by simulating rare and complex medical conditions, empowering clinicians to refine their skills in controlled environments. These transformative capabilities of generative AI have established it as a cornerstone of the future of healthcare delivery.

Why Is the Pharmaceutical Sector at the Forefront of Generative AI Adoption?

The pharmaceutical industry is experiencing a paradigm shift as generative AI accelerates drug discovery and development. This technology significantly reduces the traditionally prohibitive time and cost associated with bringing new drugs to market. AI-driven platforms identify promising molecular compounds, simulate their interactions, and predict pharmacological properties, streamlining the preclinical phase. By facilitating virtual drug trials and computational predictions, generative AI minimizes the likelihood of late-stage failures, ensuring higher success rates and faster approval processes. AI's role in drug repurposing has also proven to be a game-changer. By analyzing existing datasets and exploring new applications for established drugs, pharmaceutical companies can address unmet medical needs more efficiently. Furthermore, generative AI enhances clinical trial management by selecting optimal patient cohorts, ensuring adherence to study protocols, and analyzing real-time data to identify anomalies. These innovations not only improve the speed and accuracy of drug development but also contribute to cost-effectiveness, fostering more robust pipelines for critical therapies.

How Are Healthcare Providers Integrating Generative AI Into Operations?

Hospitals and healthcare providers are embracing generative AI to improve operational efficiency, patient care, and resource utilization. AI-powered systems are revolutionizing administrative workflows, from appointment scheduling and billing to data management and compliance monitoring, allowing healthcare staff to focus on direct patient interactions. Integrating AI with electronic health records (EHRs) ensures that clinicians have access to accurate, up-to-date information, enabling faster and more informed decision-making. Telemedicine has witnessed exponential growth, driven in part by AI-enabled virtual assistants and diagnostic tools. These platforms enhance the quality of remote consultations by offering real-time insights and monitoring capabilities, particularly in underserved and rural areas. Additionally, predictive analytics powered by AI supports hospitals in resource planning by forecasting patient admission trends and optimizing staff deployment. Robotic-assisted surgeries, guided by generative AI, are setting new benchmarks for precision and reducing recovery times. Together, these advancements reflect the growing integration of AI into healthcare ecosystems, ensuring improved outcomes for providers and patients alike.

What Factors Are Driving the Growth of the Generative AI in Healthcare Market?

The growth of the Generative Artificial Intelligence in Healthcare market is driven by several key factors, including the increasing volume of healthcare data, advancements in computational power, and the rising demand for personalized care. The adoption of AI by pharmaceutical companies has been a major catalyst, enabling faster drug discovery and reducing costs. Moreover, the expansion of telehealth services and remote care solutions has fueled demand for AI-powered platforms that facilitate seamless and efficient patient management, particularly in areas with limited healthcare access. Consumer expectations for precision medicine and tailored treatments have pushed healthcare providers to adopt generative AI tools that enhance patient satisfaction and clinical outcomes. Insurers are also turning to AI for fraud detection, risk assessment, and personalized policy creation, broadening the technology's application across the healthcare landscape. Additionally, governments and private entities are making significant investments in AI research and innovation, with regulatory bodies adapting to ensure ethical deployment and interoperability. These factors collectively underscore the transformative impact of generative AI on the healthcare sector and its role in shaping the future of global health systems.

SCOPE OF STUDY:

The report analyzes the Generative Artificial Intelligence in Healthcare market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Component (Solutions Component, Services Component); Function (Medical Imaging Analysis Function, Virtual Nursing Assistants Function, Robot-Assisted AI Surgery Function, Administrative Process Optimization Function); Application (Clinical Application, System Application); End-Use (Clinical Research End-Use, Medical Centers End-Use, Diagnostic Centers End-Use, Other End-Uses)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

Select Competitors (Total 27 Featured) -

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

III. MARKET ANALYSIS

IV. COMPETITION

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â